Return to Clinical Trials Search Results
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physicians Choice in Participants With Endometrial Cancer Who Have Received Prior
Platinum-based Chemotherapy and Immunotherapy
Primary Objective:
To compare MK-2870 to Treatment of Physician s Choice (TPC) with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR)
To compare MK-2870 to TPC with respect to overall survival (OS)
Secondary Objectives:
To compare MK-2870 to TPC with respect to objective response rate (ORR) per RECIST 1.1 by BICR in participants with measurable disease at study entry
To evaluate MK-2870 to TPC with respect to duration of response (DOR) per RECIST 1.1 by BICR in participants with measurable disease at study entry
To compare the safety and tolerability of MK-2870 to TPC
To evaluate health-related quality of life (QoL) outcome using the EORTC QLQ-30
Primary Objective:
To compare MK-2870 to Treatment of Physician s Choice (TPC) with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR)
To compare MK-2870 to TPC with respect to overall survival (OS)
Secondary Objectives:
To compare MK-2870 to TPC with respect to objective response rate (ORR) per RECIST 1.1 by BICR in participants with measurable disease at study entry
To evaluate MK-2870 to TPC with respect to duration of response (DOR) per RECIST 1.1 by BICR in participants with measurable disease at study entry
To compare the safety and tolerability of MK-2870 to TPC
To evaluate health-related quality of life (QoL) outcome using the EORTC QLQ-30
Recruitment Status
Current Studies